1[1]Summary of safety-related drug labeling changes changes approved by FDA center for drug evaluation and research(CDER).[EB/OL].2001-10-10[2006-8-25].http://www.fda.gov/med watch/safety/2001/aug01.html.
2[2]Summary of safety-related drug labeling changes changes approved by FDA center for drug evaluation and research(CDER).[EB/OL].2001-11-29[2006-8-25].http://www.fda.gov/med watch/safety/2001/oct01.html.
4[4]Saraya A,Yokokura M,Gonoi T,et al.Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitive K+channels[J].Eur J Pharmacol.2004,497:111-117.
5[5]Joseph S,Bertino Jr,Robert C,et al.Gatifloxacin-associated corrected QT interval prolongation,torsades de points and ventricular fibrillation in patients with hnown risk factors[J].CID.2002,34(15):861-863.
7[8]Frothingham R.Quinoione safety and efficacy more important than potency.[EB/OL].2004-4-5[2006-1-3].http://www.cdc.gov/ncidod/eid/vol 11no1/03-0307.html.
8[9]Frothingham R.Quinoione safety and efficacy(responses).[EB/OL].2005-5-19[2005-12-30].http://www.cdc.gov/ncidod/eid/vol 11no06/04-0740-05-0581.html.
